Application of tissue engineered vascular grafts for small-diameter artery reconstruction has been a much anticipated advance in vascular surgery. The aim of this study is to assess the effectiveness of small-diameter decellularized vascular grafts in below-knee bypass surgery for diabetic lower extremity ischemia.
Methods:
Three patients with diabetic lower limb ischemia were admitted to the Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University between May, 2010 and June, 2010. Decellularized porcine arteries with modified surface were implanted in the lower extremity for below-knee arterial revascularization. Imaging examination was performed for assessment of graft mechanical stability and patency at 1 month and 6 months after implantation.
Results:
At 6 months after implantation, all three grafts were patent with no stenosis or aneurysm formation of the grafts were found on imaging assessment with primary patency rate of 100% (3/3) both at 1 month and 6 months after graft insertion.
Conclusion:
Decellularized vascular graft with surface modification for the small-diameter artery reconstruction had good clinical results after 6 months follow-up in three patients with diabetic lower limb ischemia.
GoASMozaffarianDRogerVL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation2013; 127(1): E6–E245.
2.
DesaiNDCohenEANaylorCD, et al. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med2004; 351(22): 2302–2309.
3.
NomiMAtalaACoppiPD, et al. Principals of neovascularization for tissue engineering. Mol Aspects Med2002; 23(6): 463–483.
4.
HoerstrupSPZündGSodianR, et al. Tissue engineering of small caliber vascular grafts. Eur J Cardiothorac Surg2001; 20(1): 164–169.
5.
DahanNZarbivGSarigU, et al. Porcine small diameter arterial extracellular matrix supports endothelium formation and media remodeling forming a promising vascular engineered biograft. Tissue Eng Part A2012; 18(3–4): 411–422.
6.
SheridanWSDuffyGPMurphyBP.Mechanical characterization of a customized decellularized scaffold for vascular tissue engineering. J Mech Behav Biomed Mater2012; 8(2): 58–70.
7.
GilbertTWSellaroTLBadylakSF.Decellularization of tissues and organs. Biomaterials2006; 27(19): 3675–3683.
8.
DahlSLKohJPrabhakarV, et al. Decellularized native and engineered arterial scaffolds for transplantation. Cell Transplant2003; 12(6): 659–666.
9.
SchmidtCEBaierJM.Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials2000; 21(22): 2215–2231.
10.
ZhuCYingDMiJ, et al. Development of anti-atherosclerotic tissue-engineered blood vessel by A20-regulated endothelial progenitor cells seeding decellularized vascular matrix. Biomaterials2008; 29(17): 2628–2636.
11.
DahlSLMKypsonAPLawsonJH, et al. Readily available tissue-engineered vascular grafts. Sci Transl Med2011; 3(68): 68r–69r.
12.
UchimuraESawaYTaketaniS, et al. Novel method of preparing acellular cardiovascular grafts by decellularization with poly(ethylene glycol). J Biomed Mater Res A2003; 67(3): 834–837.
13.
XuXFGuoHPRenXJ, et al. Effect of carbodiimide cross-linking of decellularized porcine pulmonary artery valvular leaflets. Int J Clin Exp Med2014; 7(3): 649–656.
14.
KudoTChandraFAKwunWH, et al. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular versus open bypass surgery. J Vasc Surg2006; 44(2): 304–313.
15.
HawkinsJAHillmanNDLambertLM, et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg2003; 126(1): 247–252, 252–253.
16.
DohmenPMLembckeAHotzH, et al. Ross operation with a tissue-engineered heart valve. Ann Thorac Surg2002; 74(5): 1438–1442.
17.
HuynhTAbrahamGMurrayJ, et al. Remodeling of an acellular collagen graft into a physiologically responsive neovessel. Nat Biotechnol1999; 17(11): 1083–1086.
18.
KasimirMTRiederEGNigischA, et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis2006; 15(2): 278–286.
19.
ZhouJFritzeOSchleicherM, et al. Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials2010; 31(9): 2549–2554.
20.
SchoenFJLevyRJ.Founder’s Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res1999; 47(4): 439–465.
21.
SaelmanEUNieuwenhuisHKHeseKM, et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood1994; 83(5): 1244–1250.
22.
GuptaASWangSLinkE, et al. Glycocalyx-mimetic dextran-modified poly(vinyl amine) surfactant coating reduces platelet adhesion on medical-grade polycarbonate surface. Biomaterials2006; 27(16): 3084–3095.
23.
OlsonSBjörkI.Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost1994; 20(4): 373–409.
24.
WengYJHouRXieD, et al. Covalent immobilization of heparin on anatase TiO2 films via chemical adsorbent phosphoric acid interface. Key Eng Mater2007; 330–332: 865–868.
25.
WissinkMBeerninkRJPootA, et al. Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in vitro evaluation. Biomaterials2001; 22(2): 151–163.
26.
PageC.Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol2013; 2013: 910743.
27.
SarkarSSalesKMHamiltonG, et al. Addressing thrombogenicity in vascular graft construction. J Biomed Mater Res B Appl Biomater2010; 82(1): 100–108.
28.
GargHGJosephPAThompsonBT, et al. Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation. Arch Biochem Biophys1999; 371(2): 228–233.
29.
ReillyCFFritzeLMRosenbergRD.Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol1986; 129(1): 11–19.
30.
GilottiACNimlamoolWPughR, et al. Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG). J Cell Physiol2014; 229(12): 2142–2152.
31.
LiuHLiXNiuX, et al. Improved hemocompatibility and endothelialization of vascular grafts by covalent immobilization of sulfated silk fibroin on poly(lactic-co-glycolic acid) scaffolds. Biomacromolecules2011; 12(8): 2914–2924.
32.
LiuHLiXZhouG, et al. Electrospun sulfated silk fibroin nanofibrous scaffolds for vascular tissue engineering. Biomaterials2011; 32(15): 3784–3793.
33.
ZhuTYuKBhuttoMA, et al. Synthesis of RGD-peptide modified poly(ester-urethane) urea electrospun nanofibers as a potential application for vascular tissue engineering. Chem Eng J2017; 315(Complete): 177–190.
34.
NoelSFortierCMurschelF, et al. Co-immobilization of adhesive peptides and VEGF within a dextran-based coating for vascular applications. Acta Biomater2016; 37: 69–82.
35.
KhanMYangJShiC, et al. Surface tailoring for selective endothelialization and platelet inhibition via a combination of SI-ATRP and Click-chemistry using Cys–Ala–Gly-peptide. Acta Biomater2015; 20: 69–81.
36.
RuoslahtiEPierschbacherMD.New perspectives in cell adhesion: RGD and integrins. Science1987; 238(4826): 491–497.
37.
RahmanyMBVan DykeM.Biomimetic approaches to modulate cellular adhesion in biomaterials: a review. Acta Biomater2013; 9(3): 5431–5437.
38.
ChoiWSBaeJWLimHR, et al. RGD peptide-immobilized electrospun matrix of polyurethane for enhanced endothelial cell affinity. Biomed Mater2008; 3(4): 44104.
39.
SivaramanBLatourRA.The relationship between platelet adhesion on surfaces and the structure versus the amount of adsorbed fibrinogen. Biomaterials2010; 31(5): 832–839.
40.
NoelSHachemAMerhiY, et al. Development of a polyester coating combining anti-thrombogenic and cell adhesive properties – Influence of sequence and surface density of adhesion peptides. Biomacromolecules2015; 16(6): 1682–1694.
41.
WangWGuoLYuY, et al. Peptide REDV-modified polysaccharide hydrogel with endothelial cell selectivity for the promotion of angiogenesis. J Biomed Mater Res A2015; 103(5): 1703–1712.
42.
JunHWWestJL.Endothelialization of microporous YIGSR/PEG-modified polyurethaneurea. Tissue Eng2005; 11(8): 1133–1140.
43.
LeeJSLeeKMoonSH, et al. Mussel-inspired cell-adhesion peptide modification for enhanced endothelialization of decellularized blood vessels. Macromol Biosci2015; 14(8): 1181–1189.
44.
ChoiWSJinWBJoungYK, et al. Fabrication of endothelial cell-specific polyurethane surfaces co-immobilized with GRGDS and YIGSR peptides. Macromol Res2009; 17(7): 458–463.
45.
McallisterTNMaruszewskiMGarridoSA, et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet2009; 373(9673): 1440–1446.
46.
WystrychowskiWMcallisterTNZagalskiK, et al. First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access. J Vasc Surg2014; 60(5): 1353–1357.
47.
LawsonJHGlickmanMHIlzeckiM, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase two single-arm trials. Lancet2016; 387(10032): 2026–2034.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
